Galleon names Brookes senior VP

Thursday, December 1, 2011 11:38 AM

Galleon Pharmaceuticals has named Lynne M. Brookes senior vice president and chief business officer.

Brookes joins Galleon from Cephalon where she held a variety of product management, marketing and business development positions and was most recently vice president of business development.

“Lynne is uniquely well-qualified to serve as our chief business officer because of her experience launching and managing very successful pharmaceutical products in markets that include many breathing-control-disorder patients. She provides a strong commercial perspective to complement our established drug-discovery and clinical-development teams," said James C. Mannion, Ph.D., Galleon’s president, chief executive officer and founder.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs